New drugs in multiple myeloma – role of carfilzomib and pomalidomide
Carfilzomib (CFZ), an epoxyketone with specific chymotrypsin-like activity, is a second-generation proteasome inhibitor with significant activity in patients with relapsed and refractory multiple myeloma. On July 20, 2012, the US Food and Drug Administration approved CFZ to treat patients with multi...
| Main Authors: | , , , , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Termedia Publishing House
2014
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4037992/ |